Phase 1 Study of PTX-100 in Patients With Advanced Malignancies
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized study to evaluate the PD, PK, and safety of 500 to 2000
mg/m2 PTX-100 in patients with advanced malignancies.
PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle
for 4 cycles unless toxicity is observed.